GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexin Pharmaceuticals AB (OSTO:ANNX) » Definitions » Earnings per Share (Diluted)

Annexin Pharmaceuticals AB (OSTO:ANNX) Earnings per Share (Diluted) : kr-0.17 (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Annexin Pharmaceuticals AB Earnings per Share (Diluted)?

Annexin Pharmaceuticals AB's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was kr-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.17.

Annexin Pharmaceuticals AB's EPS (Basic) for the three months ended in Sep. 2024 was kr-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.17.

Annexin Pharmaceuticals AB's EPS without NRI for the three months ended in Sep. 2024 was kr-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was kr-0.17.


Annexin Pharmaceuticals AB Earnings per Share (Diluted) Historical Data

The historical data trend for Annexin Pharmaceuticals AB's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexin Pharmaceuticals AB Earnings per Share (Diluted) Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only -0.81 -0.36 -0.36 -0.26 -0.24

Annexin Pharmaceuticals AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.06 -0.04 -0.04 -0.03

Competitive Comparison of Annexin Pharmaceuticals AB's Earnings per Share (Diluted)

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexin Pharmaceuticals AB's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's PE Ratio falls into.



Annexin Pharmaceuticals AB Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Annexin Pharmaceuticals AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-44.054-0)/178.613
=-0.25

Annexin Pharmaceuticals AB's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-10.928-0)/532.979
=-0.02

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Annexin Pharmaceuticals AB  (OSTO:ANNX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Annexin Pharmaceuticals AB Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Annexin Pharmaceuticals AB's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Annexin Pharmaceuticals AB Business Description

Traded in Other Exchanges
Address
Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.